Dr. Reddy's Laboratories Ltd - Company Profile
Powered by
All the data and insights you need on Dr. Reddy's Laboratories Ltd in one report.
- Save hours of research time and resources with
our up-to-date Dr. Reddy's Laboratories Ltd Strategy Report
- Understand Dr. Reddy's Laboratories Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Dr. Reddy's Laboratories Ltd (Dr. Reddy's) is a pharmaceutical company that manufactures and markets generic formulations, active pharmaceutical ingredients (APIs), biosimilars and proprietary products. The company’s generic products are indicated for the treatment of gastrointestinal disorders, various cancer types, pain, cardiovascular diseases, central nervous system disorders, infectious diseases, and pediatric diseases. The company also develops and markets generic biosimilar products. Its pipeline includes New Chemical Entities (NCEs) that focus on the treatment of metabolic disorders, bacterial infections, pain, and inflammation. The company markets products in the US, Europe, Latin America, and Asia. Dr. Reddy's is headquartered in Hyderabad, Telangana, India.
Dr. Reddy's Laboratories Ltd premium industry data and analytics
Products and Services
Products | Services | Brands |
---|---|---|
Generic Biosimilars | Contract Manufacturing | OMEZ |
Generic Small-Molecule Drugs | Custom Pharma Services | Stamlo |
Active Pharma Ingredients | Nise | |
XYZ | XYZ | |
XYZ | XYZ | |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | New Products/Services | In May, the company introduced Doxycycline Capsules 40 mg in the US. |
2024 | Contracts/Agreements | In April, the company entered into an agreement with Nestle India to form a joint venture to take the health science nutraceutical portfolio to consumers across India and other territories. |
2024 | Contracts/Agreements | In March, the company signed a license agreement with Pharmazz to sell a first-in-class innovative drug Centhaquine in India. |
Competitor Comparison
Key Parameters | Dr. Reddy's Laboratories Ltd | Pfizer Inc | Bayer AG | Novartis AG | GSK plc |
---|---|---|---|---|---|
Headquarters | India | United States of America | Germany | Switzerland | United Kingdom |
City | Hyderabad | New York | Leverkusen | Basel | Brentford |
State/Province | Telangana | New York | Nordrhein-Westfalen | - | England |
No. of Employees | 24,832 | 88,000 | 99,723 | 76,057 | 70,212 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
K. Satish Reddy | Chairman | Executive Board | 2015 | 55 |
G V Prasad | Managing Director; Co-Chairman | Executive Board | 2021 | 62 |
Erez Israeli | Chief Executive Officer | Senior Management | 2018 | 56 |
Parag Agarwal | Chief Financial Officer | Senior Management | 2020 | 57 |
Patrick Aghanian | Chief Executive Officer - European Generics | Senior Management | 2019 | 58 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer